Surrozen Provides Corporate Update on Clinical Programs
Announces strategic prioritization of clinical programs to focus on development of SZN-043 for Alcohol-Associated Hepatitis
SZN-043
– Completed enrollment for the Phase 1a clinical trial in chronic liver disease patients and healthy volunteers
– Expect to announce Phase 1a safety and pharmacodynamic data in Q1 2024
– Expect to initiate enrollment in the Phase 1b clinical trial in patients with alcohol-associated hepatitis in 2024 and anticipate proof-of-concept data may be available in the second half of 2024
Related news for (SRZN)
- Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway
- Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update
- Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates
- Surrozen Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye Diseases
- surrozen earns $10 million milestone payment in retinal diseases collaboration